The Indian Pharmacopoeia Commission (IPC) has issued a safety alert regarding two widely-used medications, Acetazolamide and Amlodipine, due to newly discovered side effects. The monthly drug safety alert, released on June 28, 2024, emphasizes the need for patients and healthcare professionals to closely monitor and report adverse drug reactions (ADRs) associated with these medications.
Acetazolamide, commonly used in the treatment of glaucoma post-operation, has been linked to serious adverse reactions. The alert specifies the risk of “choroidal effusion or choroidal detachment,” a condition involving the accumulation of fluid in a layer of the eye. This can lead to secondary angle-closure glaucoma, a severe condition that may cause permanent vision loss if not promptly managed.
Dr. Sanjiv Gupta, director and senior eye surgeon at the i Care Centre in New Delhi, highlighted the importance of recognizing early symptoms. “Despite the efficacy of Acetazolamide in lowering intraocular pressure post-cataract surgery, clinicians must be vigilant for signs of ciliochoroidal effusion,” he stated. Symptoms such as ocular pain, headache, and blurred vision should prompt immediate evaluation and potential discontinuation of the drug. In severe cases, surgical intervention may be necessary.
Amlodipine, a medication used to treat high blood pressure and heart-related chest pain (angina), has been found to cause “Lichenoid Keratosis,” a skin condition characterized by small, reddish-brown or pink patches. Dr. Rajeev Jayadevan, former president of the Kochi wing of the Indian Medical Association, noted that while Lichenoid Keratosis is a benign, non-cancerous condition, it requires attention as it is associated with several medications.
Amlodipine works by relaxing blood vessels, thereby normalizing blood pressure and improving oxygen flow throughout the body. This action helps prevent heart-related chest pain. However, the discovery of this skin lesion underscores the necessity for healthcare professionals to monitor for this side effect and manage it accordingly.
The IPC alert advises both healthcare professionals and patients to be vigilant for the specified ADRs. Early recognition and timely intervention are crucial in preventing severe outcomes. The alert urges reporting of any encountered side effects to ensure optimal patient safety and treatment efficacy.
